Harvard Apparatus Regenerative Technology Inc (Harvard Apparatus), formerly Biostage Inc, operates as a biotechnology company. The company carries out the business of development and commercialization of regenerated organs for human transplant. It develops bioengineered organ implants based on its Cellframe technology which combines biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. Harvard Apparatus’s pipeline offerings include Cellspan bronchial implants, Cellspan esophageal implants and Cellspan tracheal implants. Its clinical stage product candidates include cell isolation and expansion; cell biology and seeding of cells on the scaffold. The company has operations across Germany, the US, Sweden and the UK. Harvard Apparatus is headquartered in Holliston, Massachusetts, the US.
Headquarters
United States of America
Address
84 October Hill Road, Suite 11, Holliston, Massachusetts, 01746
Website
www.biostage.com
Telephone
1 774 2337300
No of Employees
7
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HRGN (OTC)
EPS
XYZ
Net Income (2022)
XYZ
23.9%
(2022 vs 2021)
Market Cap*
$32.4M
Net Profit Margin (0 vs)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
Harvard Apparatus Regenerative Technology Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Cellspan Esophageal Implants |
| Cellspan Tracheal Implants |
| Cellspan Bronchial Implants |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Corporate Changes/Expansions | In July, the company changed its name to Harvard Apparatus Regenerative Technology, Inc. |
| 2016 | Corporate Changes/Expansions | In 2016, the company changed its name to Biostage and ticker to BSTG. |
| 2015 | Contracts/Agreements | In 2015, HART entered into a joint development agreement with Mayo Clinic with the intent of developing and improving regenerative medicine treatments for severe diseases. |
Competitor Comparison
| Key Parameters | Harvard Apparatus Regenerative Technology Inc | Smiths Medical (Inactive) | Vericel Corp | Athersys Inc | Organovo Holdings Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Holliston | Minneapolis | Cambridge | Cleveland | San Diego |
| State/Province | Massachusetts | Minnesota | Massachusetts | Ohio | California |
| No. of Employees | 7 | - | 305 | 24 | 15 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jerry He | Chairman; Chief Executive Officer | Executive Board | 2023 | 48 |
| Joseph Damasio | Chief Financial Officer | Senior Management | 2022 | 48 |
| William Fodor | Chief Scientific Officer | Senior Management | 2017 | 64 |
| Hong Yu | President | Senior Management | 2018 | 50 |
| Jason Jing Chen | Vice Chairman | Executive Board | 2018 | 61 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer